Tracing, managing, and monitoring of COVID patients has become the centerfold solution of heading towards a COVID free society said by Mr. Prem Sharma, CEO, Day To Day Health.
AstraZeneca has been granted Fast Track Designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction (MI) or heart attack.